Lung Cancer Trials Ask AI to find trials
Active Not RecruitingPhase 3NCT04685135
Official study title

Phase 3 Study of MRTX849 (Adagrasib) vs Docetaxel in Patients With Advanced Non-Small Cell Lung Cancer With KRAS G12C Mutation

Study summary

This Phase 3 study will evaluate the efficacy of the investigational agent MRTX849 (adagrasib) versus docetaxel in patients who have been previously treated for metastatic NSCLC with a KRAS G12C mutation.

Ask AI to explain this study
Start here

Key things to know

Main goalTreatment

This describes the study’s primary purpose.

What is being studiedMRTX849 and Docetaxel

The study team can explain what participation involves.

Who it may be forNon-small cell lung cancer (NSCLC) · KRAS · Metastatic or stage IV

These are broad labels—not an eligibility decision.

Checked against the public recordLast updated Aug 11, 2026 · Source: ClinicalTrials.gov

Is enrollment open?Active Not Recruiting

The study is underway but is not accepting new participants.

What kind of study?Phase 3

Interventional

Where is it offered?380 U.S. locations

Locations may change over time.

Who runs it?Mirati Therapeutics Inc.

Study sponsor

01
Study overview

What this study is about

Purpose
Treatment
Study type
Interventional
Phase
Phase 3
Sponsor
Mirati Therapeutics Inc.
Interventions being studied
Drug: MRTX849; Drug: Docetaxel
02
Explore related studies

How this study is categorized

These labels come from structured fields and exact terms in the public record.

Cancer type
Non-small cell lung cancer (NSCLC)→
Disease setting
Metastatic or stage IV→
Biomarkers
KRAS→
Treatment approach
Targeted therapy→Chemotherapy→
Study topics
After prior treatment→
03
Public criteria

Who may be able to participate

The sponsor separates these requirements into two groups. You do not need to interpret them alone—use them to guide a conversation with the study team.

Requirements people may need to meetInclusion criteria
  • Histologically or cytologically confirmed diagnosis of NSCLC with KRAS G12C mutation.
  • Candidacy to receive treatment with docetaxel. Crossover Inclusion Criteria:
  • Evidence of RECIST 1.1 defined disease progression on docetaxel per BICR
  • ECOG performance status 0-2
Reasons someone may not be able to joinExclusion criteria
  • Prior treatment with an agent targeting KRAS G12C (e.g., AMG 510, Sotorasib).
  • Active brain metastases. Crossover

Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.

04
Study sites

U.S. locations

  • Local Institution - 012-898Cerritos, California
  • Local Institution - 012-910Duarte, California
  • Local Institution - 012-898 DGlendale, California
  • Local Institution - 012-910-AHuntington Beach, California
  • Local Institution - 012-910-CIrvine, California
  • Local Institution - 012-910-BLong Beach, California
  • Local Institution - 012-910-FLong Beach, California
  • Local Institution - 012-910-DNewport Beach, California
  • Local Institution - 012-898 CSanta Ana, California
  • Local Institution - 012-858Santa Rosa, California
  • Local Institution - 012-910-ETorrance, California
  • Local Institution - 012-951-BDenver, Colorado

Source and freshness
Processed from ClinicalTrials.gov. Last public update: Aug 11, 2026. Always confirm current availability with the study team.

View original record ↗